On June 23, a meeting was held in Montreal between a pharmaceutical company and the ARSACS research team with respect to the outcome of the preclinical trial phase 11 currently underway on the ARSACS mice at the Douglas Institute. The complete results should be known in November 2015. See Meeting Summary.
+1 (514) 370-3625
ataxia@arsacs.com
